This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
The Cleveland Clinic Identifier:
First received: December 21, 2006
Last updated: July 6, 2011
Last verified: November 2006

RATIONALE: Lenalidomide may stop the growth of solid tumors by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with docetaxel and carboplatin may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with docetaxel and carboplatin in treating patients with advanced solid tumors.

Condition Intervention Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: carboplatin Drug: docetaxel Drug: lenalidomide Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of Three-Weekly Docetaxel, Carboplatin and Oral CC-5013 in Patients With Advanced Solid Tumors

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Maximum tolerated dose of lenalidomide
  • Dose-limiting toxicity of lenalidomide

Secondary Outcome Measures:
  • Safety and toxicity
  • Clinical activity

Enrollment: 14
Study Start Date: August 2004
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:



  • Determine the maximum tolerated dose of lenalidomide when administered with docetaxel and carboplatin in patients with advanced solid tumors.


  • Determine the safety and toxic effects of this regimen in these patients.
  • Determine, preliminarily, the clinical activity of this regimen in these patients.

OUTLINE: This is an open-label, dose-escalation study of lenalidomide.

Patients receive docetaxel IV over 1 hour followed by carboplatin IV on day 1. Patients also receive oral lenalidomide once daily on days 1-14. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease after completion of 6 courses of treatment may continue lenalidomide alone once daily on days 1-14. Patients whose disease is stable or responding after completing 2 or 4 courses and who are unable to tolerate further chemotherapy may continue lenalidomide alone once daily on days 1-14, at the investigator's discretion. Treatment with lenalidomide repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of lenalidomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 6-8 patients are treated at the MTD.

After completion of study treatment, patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 42 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically proven solid tumor
  • Measurable or evaluable disease
  • Refractory to standard treatment
  • No prior failure of a docetaxel and carboplatin regimen except in the adjuvant setting
  • History of brain disease allowed, provided the following criteria are met:

    • Brain disease previously treated with radiotherapy or surgery
    • Asymptomatic with no active brain disease, as documented by CT scan or MRI, for at least 3 months


  • ECOG performance status 0-2
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Creatinine ≤ 1.5 mg/dL
  • Bilirubin normal
  • AST and ALT ≤ 2 times upper limit of normal (ULN) (5 times ULN if hepatic metastases are present)
  • Alkaline phosphatase ≤ 3 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
  • No serious medical condition, laboratory abnormality, or psychiatric illness that would preclude giving informed consent, expose the patient to unacceptable risk, or affect the interpretation of study data
  • No known hypersensitivity to thalidomide
  • No history of erythema nodosum, characterized by a desquamating rash, while taking thalidomide or similar drugs
  • No pre-existing peripheral neuropathy ≥ grade 2
  • No known hypersensitivity or intolerance to taxanes
  • No known HIV positivity
  • No known infectious hepatitis, types A, B, or C


  • See Disease Characteristics
  • No more than 2 prior chemotherapy regimens
  • At least 28 days since prior cancer therapy, including radiotherapy, biologic therapy, hormonal therapy, chemotherapy, or surgery
  • At least 28 days since any other prior investigational drug or therapy
  • No prior lenalidomide
  • No other concurrent chemotherapy or biologic therapy
  • No concurrent radiotherapy
  • No concurrent use of any other anticancer agents or treatments
  • No prophylactic granulocyte colony-stimulating factors (G-CSF) during the first course of study treatment
  • No concurrent prophylactic antibiotics
  • No concurrent treatment with the following medications:

    • Systemic corticosteroids (except as prophylaxis for docetaxel administration)
    • Estrogens
    • Azoles
    • Macrolides
    • Cyclosporine
    • Rifampin
    • Phenytoin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415116

Sponsors and Collaborators
The Cleveland Clinic
National Cancer Institute (NCI)
Study Chair: Tarek M. Mekhail, MD Case Comprehensive Cancer Center
  More Information

Responsible Party: Tarek Mekhail, Cleveland Clinic Taussing Cancer Institute Identifier: NCT00415116     History of Changes
Other Study ID Numbers: CASE-CCF-7216
P30CA043703 ( US NIH Grant/Contract Award Number )
Study First Received: December 21, 2006
Last Updated: July 6, 2011

Keywords provided by The Cleveland Clinic:
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors processed this record on June 22, 2017